Rheumatoid arthritis

Comorbidity in incident rheumatoid arthritis: a nationwide case-control study with bidirectional follow-up

Rheumatology (Oxford)Published Case-control study

Authors' conclusion

Enhanced risk of multiple concurrent disorders was observed both pre- and post-RA Dx, with varying patterns across different disease groups.

Study context

Population
All available healthcare claims for Poland, 2011–2021; prevalent rheumatoid arthritis (RA) examined for morbidity patternsmatched 1:10 · prevalent RA 262,265
Comparison
Incident RA vs matched controls from the general population
  • Incident RAn = 15,879
Outcome
Risk of concurrent disorders pre- and post-RA Dx
Follow-up
Five years before and after Dx
Methodological detailsretrospective, nationwide, age-, sex- and region-matched controls 1:10, bidirectional five-year follow-up
  • Retrospective
  • Nationwide
  • Age-, sex- and region-matched controls 1:10
  • Bidirectional five-year follow-up

Main finding

As reported in the abstract

Risk of concomitant disorders pre- and post-Dx, by disease group · bidirectional 5-year timeframe from RA Dx
RAIncidence rate ratio (95% CI)
Hematologic conditions
1.80(1.58–2.05)
Pulmonary conditions
1.57(1.53–1.62)
Gastrointestinal conditions
1.53(1.46–1.60)
Cardiovascular conditions
1.25(1.22–1.27)

Observational data: associations, not effects.

Further findings

ILD, pre- and post-Dx

IRR (95% CI)
RApre-Dx2.97 (2.20–4.02)
RApost-Dx4.66 (3.91–5.56)

Inflammatory bowel disease, pre- and post-Dx

IRR (95% CI)
RApre-Dx1.61 (1.25–2.07)
RApost-Dx2.12 (1.70–2.63)

Thyroid cancer, post-Dx

IRR (95% CI)
RA1.29 (1.00–1.66)

Lymphoma, post-Dx

IRR (95% CI)
RA1.50 (1.20–1.88)

Colon cancer, post-Dx (reduced risk)

IRR (95% CI)
RA0.77 (0.62–0.94)

Original publication

Comorbidity in incident rheumatoid arthritis: a nationwide case-control study with bidirectional follow-up. Rheumatology (Oxford). Published 17 December 2024. doi:10.1093/rheumatology/keae670

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.